[HTML][HTML] Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
[HTML][HTML] Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
S Dryden-Peterson, A Kim, AY Kim, EC Caniglia… - 2022 - europepmc.org
Background In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
S Dryden-Peterson, A Kim, AY Kim, EC Caniglia… - medRxiv, 2022 - medrxiv.org
Abstract Background In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction
in hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
in hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
S Dryden-Peterson, A Kim, AY Kim… - … : the preprint server …, 2022 - pubmed.ncbi.nlm.nih.gov
Background In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
S Dryden-Peterson, A Kim, AY Kim, EC Caniglia… - medRxiv, 2022 - medrxiv.org
Abstract Background In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction
in hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
in hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system.
S Dryden-Peterson, A Kim, AY Kim… - Medrxiv: the Preprint …, 2022 - europepmc.org
Background In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …